Kyle Piskel Biography and Net Worth

Kyle Piskel is the Chief Financial Officer at Adaptive Biotechnologies, a commercial-stage biotech company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease. Since joining Adaptive in 2015, Kyle has held various positions of ascending responsibility within finance and accounting, including Corporate Controller and Principal Accounting Officer. Prior to joining Adaptive, Kyle worked at Expedia Group and Ernst & Young, LLP. Kyle is a Certified Public Accountant.

What is Kyle Piskel's net worth?: The estimated net worth of Kyle Piskel is at least $3.78 million as of November 28th, 2025. Mr. Piskel owns 216,637 shares of Adaptive Biotechnologies stock worth more than $3,782,482 as of December 4th. This net worth estimate does not reflect any other investments that Mr. Piskel may own. Additionally, Mr. Piskel receives an annual salary of $375,900.00 as CFO at Adaptive Biotechnologies. Learn More about Kyle Piskel's net worth.
How old is Kyle Piskel?: Mr. Piskel is currently 40 years old. There are 7 older executives and no younger executives at Adaptive Biotechnologies. The oldest executive at Adaptive Biotechnologies is Ms. Stacy L. Taylor, Senior VP, General Counsel & Corporate Secretary, who is 64 years old. Learn More on Kyle Piskel's age.
What is Kyle Piskel's salary?: As the CFO of Adaptive Biotechnologies Corporation, Mr. Piskel earns $375,900.00 per year. There are 4 executives that earn more than Mr. Piskel. The highest earning executive at Adaptive Biotechnologies is Mr. Chad M. Robins M.B.A., Co-Founder, CEO & Chairman, who commands a salary of $1,000,000.00 per year. Learn More on Kyle Piskel's salary.
How do I contact Kyle Piskel?: The corporate mailing address for Mr. Piskel and other Adaptive Biotechnologies executives is 1551 EASTLAKE AVENUE EAST SUITE 200, SEATTLE WA, 98102. Adaptive Biotechnologies can also be reached via phone at (206) 659-0067 and via email at [email protected]. Learn More on Kyle Piskel's contact information.
Has Kyle Piskel been buying or selling shares of Adaptive Biotechnologies?: During the past quarter, Kyle Piskel has sold $3,178,333.90 in Adaptive Biotechnologies stock. Most recently, Kyle Piskel sold 162,820 shares of the business's stock in a transaction on Friday, November 28th. The shares were sold at an average price of $19.50, for a transaction totalling $3,174,990.00. Following the completion of the sale, the chief financial officer now directly owns 216,637 shares of the company's stock, valued at $4,224,421.50. Learn More on Kyle Piskel's trading history.
Who are Adaptive Biotechnologies' active insiders?: Adaptive Biotechnologies' insider roster includes R. Adams (COO), Lance Baldo (Insider), Sharon Benzeno (Insider), Chad Cohen (CFO), Egon Durban (Director), David Goel (Director), Michelle Griffin (Director), Robert Hershberg (Director), Francis Lo (Insider), Peter Neupert (Director), Jyoti Palaniappan (SVP), Kyle Piskel (CFO), Chad Robins (CEO), Chad Robins (CEO), Harlan Robins (Insider), Julie Rubinstein (President), and Stacy Taylor (SVP). Learn More on Adaptive Biotechnologies' active insiders.
Are insiders buying or selling shares of Adaptive Biotechnologies?: During the last twelve months, insiders at the sold shares 23 times. They sold a total of 1,857,401 shares worth more than $24,417,086.33. The most recent insider tranaction occured on December, 1st when CEO Chad M Robins sold 124,998 shares worth more than $2,367,462.12. Insiders at Adaptive Biotechnologies own 6.4% of the company. Learn More about insider trades at Adaptive Biotechnologies.
Information on this page was last updated on 12/1/2025.

Kyle Piskel Insider Trading History at Adaptive Biotechnologies

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
11/28/2025	Sell	162,820	$19.50	$3,174,990.00	216,637
11/17/2025	Sell	238	$14.05	$3,343.90	269,343
5/16/2025	Sell	1,929	$8.89	$17,148.81	277,396
3/5/2025	Sell	10,320	$6.98	$72,033.60	269,010
11/18/2024	Sell	248	$4.98	$1,235.04	154,330
3/5/2024	Sell	7,727	$3.43	$26,503.61	123,318
11/16/2023	Sell	259	$4.13	$1,069.67	87,305
3/6/2023	Sell	3,529	$8.57	$30,243.53	87,564
11/16/2022	Sell	959	$8.87	$8,506.33	46,706

Kyle Piskel Buying and Selling Activity at Adaptive Biotechnologies

Adaptive Biotechnologies Company Overview

Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system. It also provides clonoSEQ diagnostic test which detects and monitors the remaining number of cancer cells that are present in a patient's body during and after treatment, known as Minimal Residual Disease (MRD). The company offers products and services for life sciences research, clinical diagnostics, and drug discovery applications. Adaptive Biotechnologies Corporation has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers; and Microsoft Corporation to develop diagnostic tests for the early detection of various diseases from a single blood test. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.

Today's Range

Now: $17.46

$16.45

$17.58

50 Day Range

MA: $16.33

$13.22

$20.46

2 Week Range

Now: $17.46

$5.80

$20.76

Volume

2,927,169 shs

Average Volume

2,488,783 shs

Market Capitalization

$2.67 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.2

Kyle Piskel Biography and Net Worth

What is Kyle Piskel's net worth?

How old is Kyle Piskel?

What is Kyle Piskel's salary?

How do I contact Kyle Piskel?

Has Kyle Piskel been buying or selling shares of Adaptive Biotechnologies?

Who are Adaptive Biotechnologies' active insiders?

Are insiders buying or selling shares of Adaptive Biotechnologies?